Tirzepatide, the active ingredient in both Mounjaro for type 2 diabetes and Zepbound for weight loss, was in short supply for more than two years. But the drugmaker Eli Lilly is “currently meeting or exceeding demand” for all doses of these medicines and should continue to do so going forward, the FDA said in a December 19 statement.

The US FDA re-issued a decision first made by the agency in October that a shortage of the diabetes/weight-loss medication tirzepatide is over.

The Food and Drug Administration (FDA) has reaffirmed that Mounjaro and Zepbound are no longer in shortage following a reevaluation of its decision to remove it from the federal drug shortage list

The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli Lilly’s diabetes and weight loss drugs Mounjaro and Zepbound — is over.

The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a limited grace period before taking any enforcement actions.